Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  tamoxifen citrate
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011H2301, NCI-2017-00678, NCT03081234
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239
Pembrolizumab, Tamoxifen Citrate, and Vorinostat in Treating Patients with Hormone Receptor Positive Stage IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC #147523, NCI-2015-00815, 132069, 14-15383, 147523, NCT02395627
Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-052, NCI-2016-00893, NCT02764541
Fulvestrant and Tamoxifen Citrate in Treating Patients with Estrogen Receptor Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UPCI 16-015, NCI-2016-01578, NCT02913430
Tamoxifen Citrate or Afimoxifene in Treating Patients with Estrogen Receptor Positive Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NCI2015-06-04, NCI-2016-01911, N01-CN-2012-00035, NWU2015-06-04, NCT02993159
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BTCRC BRE15-016, NCI-2017-00376, NCT02668666
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16339, NCI-2017-00442, 2016-000288-18, I3Y-MC-JPCG, NCT02747004
Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: IRB15-1005, NCI-2017-00754, NCT03058939
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15252, NCI-2014-01032, I3Y-MC-JPBH, NCT02057133
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
Start Over